Document:

Exhibit 4.2SeptIndent5thSupIndent

Exhibit 4.2

FIFTH SUPPLEMENTAL INDENTURE
FIFTH SUPPLEMENTAL INDENTURE, dated as of July 3, 2012 (the "Fifth Supplemental Indenture"), by and among Valeant Pharmaceuticals Holdings (Barbados) SRL, Valeant International Bermuda, Valeant Laboratories International Bermuda, Valeant Pharmaceuticals Holdings Bermuda, Valeant Pharmaceuticals Nominee Bermuda, Valeant Pharmaceuticals Luxembourg S.à.r.l., Valeant Pharmaceuticals Ireland (collectively, the “New Guarantors”), Valeant Pharmaceuticals International, a Delaware corporation (the "Company") and The Bank of New York Mellon Trust Company, N.A., a national banking association, as trustee (the "Trustee").
WHEREAS, each of the Company, Valeant Pharmaceuticals International, Inc. ("Parent"), the indirect parent of the Company, and the Subsidiary Guarantors (as defined in the Indenture referred to below) has heretofore executed and delivered to the Trustee an Indenture, dated as of September 28, 2010 (the "Indenture"), providing for the issuance of 6.75% Senior Notes due 2017 and 7.00% Senior Notes due 2020 (collectively, the "Securities");
WHEREAS, each New Guarantor desires to provide a full and unconditional guarantee (the "Guarantee") of the obligations of the Company under the Securities and the Indenture on the terms and conditions set forth herein;
WHEREAS, pursuant to Section 9.1 of the Indenture, the Company, the Trustee and the New Guarantor are authorized to execute and deliver this Fifth Supplemental Indenture; and
 WHEREAS, the Company has complied with all conditions precedent provided for in the Indenture relating to the Fifth Supplemental Indenture.
NOW THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the parties hereto mutually covenant and agree for the equal and ratable benefit of the Holders as follows:
1.    Definitions.  Capitalized terms used but not defined herein have the meanings ascribed to such terms in the Indenture.  
2.    Guarantee.  Each of the New Guarantors hereby agrees to provide a full and unconditional guarantee on the terms and subject to the conditions set forth in the Note Guarantee and in the Indenture including, but not limited to, Article 10 thereof.
3.    Effectiveness of Fifth Supplemental Indenture.  This Fifth Supplemental Indenture shall become effective upon the execution and delivery of this Fifth Supplemental Indenture by the Company, each New Guarantor and the Trustee.
4.    Indenture Remains in Full Force and Effect.  This Fifth Supplemental Indenture shall form a part of the Indenture for all purposes and, except as supplemented or amended hereby, all other provisions in the Indenture and the Securities, to the extent not inconsistent with the terms and provisions of this Fifth Supplemental Indenture, shall remain in full force and effect.
5.    No Recourse Against Others.  No stockholder, officer, director or incorporator, as such, past, present or future of any New Guarantor shall have any personal liability under this Guarantee, 

1

the Securities, the Indenture or this Fifth Supplemental Indenture by reason of his, her or its status as such stockholder, officer, director or incorporator.
6.    Headings.  The headings of the Articles and Sections of this Fifth Supplemental Indenture are inserted for convenience of reference and shall not be deemed a part thereof.
7.    Counterparts.  This Fifth Supplemental Indenture may be executed in any number of counterparts, each of which so executed shall be deemed to be an original, but all such counterparts shall together constitute but one and the same instrument.
8.    Governing Law.  This Fifth Supplemental Indenture shall be governed by, and construed in accordance with, the laws of the State of New York, without regard to principles of conflicts of laws.
9.    Agent for Service.  Each New Guarantor hereby appoints CT Corporation as its authorized agent upon whom process may be served in any suit or proceeding arising out of or relating to the Indenture, the Securities or this Fifth Supplemental Indenture that may be instituted in any federal or state court in the State of New York or brought under federal or state securities laws.
10.    Trustee Disclaimer.  The Trustee is not responsible for the validity or sufficiency of this Fifth Supplemental Indenture nor for the recitals herein.
[Intentionally Left Blank]

2

IN WITNESS WHEREOF, the parties hereto have caused this Fifth Supplemental Indenture to be duly executed as of the day and year first written above.

	
						
	Company:
	VALEANT PHARMACEUTICALS INTERNATIONAL

	 
	 
	 
	 

	 
	By:
	/s/ Rajiv De Silva
	 

	 
	 
	Name:
	Rajiv De Silva

	 
	 
	Title:
	President and Chief Operating Officer

	 
	 
	 
	 

3

	
						
	New Guarantors:
	VALEANT PHARMACEUTICALS HOLDINGS (BARBADOS) SRL

	 
	 
	 
	 

	 
	By:
	/s/ Mauricio Zavala
	 

	 
	 
	Name:
	Mauricio Zavala

	 
	 
	Title:
	Manager and Assistant Secretary

	 
	 
	 
	 

	 
	 
	 
	 

	 
	By:
	/s/ Rich Wichansky
	 

	 
	 
	Name:
	Rich Wichansky

	 
	 
	Title:
	Manager

	 
	 
	 
	 

4

	
						
	 
	VALEANT PHARMACEUTICALS LUXEMBOURG S.à r.l.

	 
	 
	 
	 

	 
	By:
	/s/ Bruce Goins
	 

	 
	 
	Name:
	Bruce Goins

	 
	 
	Title:
	Manager

	 
	 
	 
	 

	 
	 
	 
	 

	 
	By:
	/s/ Kuy Ly Ang
	 

	 
	 
	Name:
	Kuy Ly Ang

	 
	 
	Title:
	Manager

	 
	 
	 
	 

5

	
						
	 
	GIVEN UNDER THE COMMON SEAL OF
VALEANT PHARMACEUTICALS IRELAND
and DELIVERED as a DEED
in the presence of

	 
	 
	 
	 

	 
	 
	/s/ Graham Jackson
	 

	 
	 
	Name:
	Graham Jackson

	 
	 
	Title:
	Director and General Manager

	 
	 
	 
	 

	 
	 
	 
	 

	 
	 
	/s/ Garrett Dempsey
	 

	 
	 
	Name:
	Garrett Dempsey

	 
	 
	Title:
	Director

	 
	 
	 
	 

6

	
						
	

	VALEANT INTERNATIONAL BERMUDA

	 
	 
	 
	 

	 
	By:
	/s/ Peter McCurdy
	 

	 
	 
	Name:
	Peter McCurdy

	 
	 
	Title:
	Director, President and Assistant Secretary

	 
	 
	 
	 

	 
	 
	 
	 

	 
	By:
	/s/ Simon Payne
	 

	 
	 
	Name:
	Simon Payne

	 
	 
	Title:
	Director

	 
	 
	 
	 

	
						
	 
	VALEANT LABORATORIES INTERNATIONAL BERMUDA

	 
	 
	 
	 

	 
	By:
	/s/ Peter McCurdy
	 

	 
	 
	Name:
	Peter McCurdy

	 
	 
	Title:
	Director, President and Assistant Secretary

	 
	 
	 
	 

	 
	 
	 
	 

	 
	By:
	/s/ Simon Payne
	 

	 
	 
	Name:
	Simon Payne

	 
	 
	Title:
	Director

	 
	 
	 
	 

	
						
	 
	VALEANT PHARMACEUTICALS HOLDINGS BERMUDA

	 
	 
	 
	 

	 
	By:
	/s/ Peter McCurdy
	 

	 
	 
	Name:
	Peter McCurdy

	 
	 
	Title:
	Director, President and Assistant Secretary

	 
	 
	 
	 

	 
	 
	 
	 

	 
	By:
	/s/ Simon Payne
	 

	 
	 
	Name:
	Simon Payne

	 
	 
	Title:
	Director

	 
	 
	 
	 

7

	
						
	 
	VALEANT PHARMACEUTICALS NOMINEE BERMUDA

	 
	 
	 
	 

	 
	By:
	/s/ Peter McCurdy
	 

	 
	 
	Name:
	Peter McCurdy

	 
	 
	Title:
	Director, President and Assistant Secretary

	 
	 
	 
	 

	 
	 
	 
	 

	 
	By:
	/s/ Simon Payne
	 

	 
	 
	Name:
	Simon Payne

	 
	 
	Title:
	Director

8

	
						
	Trustee:
	THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A.  
as Trustee

	 
	 
	 
	 

	 
	By:
	/s/ Melonee Young
	 

	 
	 
	Name:
	Melonee Young

	 
	 
	Title:
	Authorized Signatory

	 
	 
	 
	 

9Exhibit4.3NovIndent4thSupIndent

Exhibit 4.3

FOURTH SUPPLEMENTAL INDENTURE
FOURTH SUPPLEMENTAL INDENTURE, dated as of July 3, 2012 (the "Fourth Supplemental Indenture"), by and among Valeant Pharmaceuticals Holdings (Barbados) SRL, Valeant International Bermuda, Valeant Laboratories International Bermuda, Valeant Pharmaceuticals Holdings Bermuda, Valeant Pharmaceuticals Nominee Bermuda, Valeant Pharmaceuticals Luxembourg S.à.r.l., Valeant Pharmaceuticals Ireland (collectively, the “New Guarantors”), Valeant Pharmaceuticals International, a Delaware corporation (the "Company"), and The Bank of New York Mellon Trust Company, N.A., a national banking association, as trustee (the "Trustee").
WHEREAS, each of the Company, Valeant Pharmaceuticals International, Inc. ("Parent"), the indirect parent of the Company, and the Subsidiary Guarantors (as defined in the Indenture referred to below) has heretofore executed and delivered to the Trustee an Indenture, dated as of November 23, 2010 (the "Indenture"), providing for the issuance of 6.875% Senior Notes due 2018 (the "Securities");
WHEREAS, each New Guarantor desires to provide a full and unconditional guarantee (the "Guarantee") of the obligations of the Company under the Securities and the Indenture on the terms and conditions set forth herein;
WHEREAS, pursuant to Section 9.1 of the Indenture, the Company, the Trustee and the New Guarantors are authorized to execute and deliver this Fourth Supplemental Indenture; and
 WHEREAS, the Company has complied with all conditions precedent provided for in the Indenture relating to the Fourth Supplemental Indenture.
NOW THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the parties hereto mutually covenant and agree for the equal and ratable benefit of the Holders as follows:
1.    Definitions.  Capitalized terms used but not defined herein have the meanings ascribed to such terms in the Indenture.  
2.    Guarantee.  Each of the New Guarantors hereby agrees to provide a full and unconditional guarantee on the terms and subject to the conditions set forth in the Note Guarantee and in the Indenture including, but not limited to, Article 10 thereof.
3.    Effectiveness of Fourth Supplemental Indenture.  This Fourth Supplemental Indenture shall become effective upon the execution and delivery of this Fourth Supplemental Indenture by the Company, each New Guarantor and the Trustee.
4.    Indenture Remains in Full Force and Effect.  This Fourth Supplemental Indenture shall form a part of the Indenture for all purposes and, except as supplemented or amended hereby, all other provisions in the Indenture and the Securities, to the extent not inconsistent with the terms and provisions of this Fourth Supplemental Indenture, shall remain in full force and effect.
5.    No Recourse Against Others.  No stockholder, officer, director or incorporator, as such, past, present or future of any New Guarantor shall have any personal liability under this Guarantee, the Securities, the Indenture or this Fourth Supplemental Indenture by reason of his, her or its status as 

1

such stockholder, officer, director or incorporator.
6.    Headings.  The headings of the Articles and Sections of this Fourth Supplemental Indenture are inserted for convenience of reference and shall not be deemed a part thereof.
7.    Counterparts.  This Fourth Supplemental Indenture may be executed in any number of counterparts, each of which so executed shall be deemed to be an original, but all such counterparts shall together constitute but one and the same instrument.
8.    Governing Law.  This Fourth Supplemental Indenture shall be governed by, and construed in accordance with, the laws of the State of New York, without regard to principles of conflicts of laws.
9.    Agent for Service.  Each New Guarantor hereby appoints CT Corporation as its authorized agent upon whom process may be served in any suit or proceeding arising out of or relating to the Indenture, the Securities or this Fourth Supplemental Indenture that may be instituted in any federal or state court in the State of New York or brought under federal or state securities laws.
10.    Trustee Disclaimer.  The Trustee is not responsible for the validity or sufficiency of this Fourth Supplemental Indenture nor for the recitals herein.
[Intentionally Left Blank]

2

IN WITNESS WHEREOF, the parties hereto have caused this Fourth Supplemental Indenture to be duly executed as of the day and year first written above.

	
						
	Company:
	VALEANT PHARMACEUTICALS INTERNATIONAL

	 
	 
	 
	 

	 
	By:
	/s/ Rajiv De Silva
	 

	 
	 
	Name:
	Rajiv De Silva

	 
	 
	Title:
	President and Chief Operating Officer

	 
	 
	 
	 

3

	
						
	New Guarantors:
	VALEANT PHARMACEUTICALS HOLDINGS (BARBADOS) SRL

	 
	 
	 
	 

	 
	By:
	/s/ Mauricio Zavala
	 

	 
	 
	Name:
	Mauricio Zavala

	 
	 
	Title:
	Manager and Assistant Secretary

	 
	 
	 
	 

	 
	 
	 
	 

	 
	By:
	/s/ Rich Wichansky
	 

	 
	 
	Name:
	Rich Wichansky

	 
	 
	Title:
	Manager

	 
	 
	 
	 

4

	
						
	 
	VALEANT PHARMACEUTICALS LUXEMBOURG S.à.r.l.

	 
	 
	 
	 

	 
	By:
	/s/ Bruce Goins
	 

	 
	 
	Name:
	Bruce Goins

	 
	 
	Title:
	Manager

	 
	 
	 
	 

	 
	 
	 
	 

	 
	By:
	/s/ Kuy Ly Ang
	 

	 
	 
	Name:
	Kuy Ly Ang

	 
	 
	Title:
	Manager

	 
	 
	 
	 

5

	
						
	 
	GIVEN UNDER THE COMMON SEAL OF
VALEANT PHARMACEUTICALS IRELAND
and DELIVERED as a DEED
in the presence of

	 
	 
	 
	 

	 
	 
	/s/ Graham Jackson
	 

	 
	 
	Name:
	Graham Jackson

	 
	 
	Title:
	Director and General Manager

	 
	 
	 
	 

	 
	 
	 
	 

	 
	 
	/s/ Garrett Dempsey
	 

	 
	 
	Name:
	Garrett Dempsey

	 
	 
	Title:
	Director

	 
	 
	 
	 

6

	
						
	

	VALEANT INTERNATIONAL BERMUDA

	 
	 
	 
	 

	 
	By:
	/s/ Peter McCurdy
	 

	 
	 
	Name:
	Peter McCurdy

	 
	 
	Title:
	Director, President and Assistant Secretary

	 
	 
	 
	 

	 
	 
	 
	 

	 
	By:
	/s/ Simon Payne
	 

	 
	 
	Name:
	Simon Payne

	 
	 
	Title:
	Director

	 
	 
	 
	 

	
						
	 
	VALEANT LABORATORIES INTERNATIONAL BERMUDA

	 
	 
	 
	 

	 
	By:
	/s/ Peter McCurdy
	 

	 
	 
	Name:
	Peter McCurdy

	 
	 
	Title:
	Director, President and Assistant Secretary

	 
	 
	 
	 

	 
	 
	 
	 

	 
	By:
	/s/ Simon Payne
	 

	 
	 
	Name:
	Simon Payne

	 
	 
	Title:
	Director

	 
	 
	 
	 

	
						
	 
	VALEANT PHARMACEUTICALS HOLDINGS BERMUDA

	 
	 
	 
	 

	 
	By:
	/s/ Peter McCurdy
	 

	 
	 
	Name:
	Peter McCurdy

	 
	 
	Title:
	Director, President and Assistant Secretary

	 
	 
	 
	 

	 
	 
	 
	 

	 
	By:
	/s/ Simon Payne
	 

	 
	 
	Name:
	Simon Payne

	 
	 
	Title:
	Director

	 
	 
	 
	 

7

	
						
	 
	VALEANT PHARMACEUTICALS NOMINEE BERMUDA

	 
	 
	 
	 

	 
	By:
	/s/ Peter McCurdy
	 

	 
	 
	Name:
	Peter McCurdy

	 
	 
	Title:
	Director, President and Assistant Secretary

	 
	 
	 
	 

	 
	 
	 
	 

	 
	By:
	/s/ Simon Payne
	 

	 
	 
	Name:
	Simon Payne

	 
	 
	Title:
	Director

8

	
						
	Trustee:
	THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A.  
as Trustee

	 
	 
	 
	 

	 
	By:
	/s/ Melonee Young
	 

	 
	 
	Name:
	Melonee Young

	 
	 
	Title:
	Authorized Signatory

	 
	 
	 
	 

9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}]]